So I was wondering if you could tell us how that went.

Well, it went really quite well.

Um, I'm horribly biased of course, but most of the chairs seemed occu- occupied, and they re- remained in the room, so I was very pleased.

Um, I think it was compliments to the panel really that, that I was blessed with.

Um, the session really validated what we set out to explore, and that that is specifically that Europe really doesn't have a science problem.

It, it has a get it right early out of the gate problem.

Um, I-- we heard from investors and biotech leaders on the panel who confirm what our own consulting experts have been seeing, and that's specifically the companies that are winning funding and getting the partnerships right are now the ones, similar to Charlotte's earlier point, that are making the sharper strategic choices up front so that they can enable flawless execution, right? So it, it's tighter, smarter decision-making, earlier, more integrated decisions that de-risk drug development, attract investment, and move more rapidly through the, the variety of challenges that, that all developers face.

So I was wondering if both of you wanted to share with listeners your respective thoughts on AI and drug development and indeed medical leadership in drug development today and tomorrow.